Viral Rhinitis
Clinical Snapshot
Viral rhinitis — the common cold — is a benign, self-limited infection of the upper respiratory tract caused by more than 200 different respiratory viruses, most often rhinovirus, followed by coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, and enterovirus.[1] Viral contact with the nasal mucosa triggers increased vascular permeability, glandular secretion, and vasodilatation — a direct inflammatory response, not a histamine-mediated allergic process — which is why drugs that help an allergic process (intranasal corticosteroids, second-generation antihistamines) generally do not help a cold, and why the drugs that do help here (decongestants, anticholinergic agents, first-generation antihistamines used for their anticholinergic effect) work through a different mechanism entirely. Symptoms typically peak around day 2-4 and resolve within 7-10 days without treatment, though cough can persist up to 3 weeks in a substantial minority of patients; no available treatment shortens the underlying illness or prevents complications such as otitis media or bacterial rhinosinusitis — every therapy discussed in this chapter is purely symptomatic.
Recognize the Condition
Typical presentation
Onset is gradual over 1-2 days. A sore throat is often the earliest symptom and usually resolves within a few days, followed by nasal congestion, rhinorrhea, sneezing, and cough. Nasal discharge often becomes thicker and discoloured (yellow or green) as the illness progresses, as neutrophils are recruited to the mucosa — this reflects the normal inflammatory course of a viral infection, not bacterial superinfection, and is not on its own a reason to suspect or treat a bacterial cause. Fever is infrequent in adults but common in children. Symptoms peak around day 2-4 and begin resolving by day 7; the full course usually runs 7-10 days, though cough can persist up to 3 weeks in some patients.
Common causative viruses
Rhinovirus
The single most common cause across all age groups, with more than 100 identified serotypes. More prevalent in fall and spring. Hand-to-hand contact is the major transmission route.
Coronavirus
The second most common cause of the classic common-cold presentation. More prevalent in mid-winter and early spring. Distinct from the pandemic coronaviruses (SARS-CoV-2), which can cause a similar but sometimes more severe presentation.
Other respiratory viruses
Respiratory syncytial virus, adenovirus, parainfluenza virus, and enterovirus each also cause a common-cold-type presentation and are difficult to distinguish clinically from rhinovirus or coronavirus infection.
Viral replication peaks within 48 hours of infection, but shedding can continue for up to 3 weeks — a patient can remain contagious well after feeling better.
Risk Factors
- Close contact with an infected person, particularly hand-to-hand contact — the dominant transmission route for rhinovirus.
- Young age — children average considerably more colds per year than adults.
- Daycare or school attendance, and other crowded settings.
- Fall, winter, and early spring seasons (rhinovirus peaks in fall/spring; coronavirus peaks in mid-winter/early spring); less common in summer.
- Tobacco or e-cigarette use, or second-hand smoke exposure.
- Immunocompromising conditions, which can prolong or worsen the course of illness.
Red Flags & Refer
An uncomplicated cold follows a predictable course — symptoms peak by day 2-4 and begin improving by day 7. Reassess rather than continuing routine symptomatic management for any of the following:
- Symptoms persisting beyond the expected 10-14 day course, or worsening after an initial period of improvement (a biphasic pattern) — this suggests a secondary bacterial complication rather than an ordinary prolonged cold.
- High fever (over 39°C) or systemic toxicity (marked malaise, rigors, appearing unwell out of proportion to a cold) — inconsistent with an uncomplicated viral illness.
- Unilateral or severe facial/sinus pain, pain on bending forward, or periorbital swelling or redness — suggests bacterial rhinosinusitis or an orbital complication rather than uncomplicated rhinitis.
- New or worsening ear pain, ear pulling in a young child, or a bulging tympanic membrane — suggests acute otitis media.
- Respiratory distress, wheeze out of proportion to a simple cold, stridor, or hypoxemia.
- Fever in an infant under 3 months of age — always needs urgent, separate assessment rather than routine cold management.
- A spasmodic or paroxysmal coughing pattern, an inspiratory whoop, or post-tussive vomiting — suggests pertussis, especially with a known local outbreak or incomplete immunization.
- Symptoms suggesting influenza or COVID-19 in a patient at high risk of complications, where antiviral therapy may change management.
Assessment & Diagnosis
Distinguishing viral rhinitis from its mimics
Viral rhinitis, allergic rhinitis, influenza, and COVID-19 can all present with nasal and respiratory symptoms early on, but the correct management differs substantially between them.
| Feature | Viral rhinitis (common cold) | Allergic rhinitis | Influenza | COVID-19 |
|---|---|---|---|---|
| Onset | Gradual, over 1-2 days | Rapid after allergen exposure; chronic or recurrent pattern | Abrupt, often within hours | Variable, often gradual over 1-3 days |
| Itching/sneezing | Sneezing common; itching uncommon | Prominent itching of the eyes, nose, and palate with paroxysmal sneezing — the hallmark feature | Uncommon | Uncommon |
| Fever | Infrequent in adults, more common in children; usually low-grade | Absent | Common, often high and abrupt | Common, variable severity |
| Systemic symptoms | Mild malaise | Absent — symptoms are localized to the nose/eyes | Prominent: severe myalgia, headache, fatigue, anorexia | Variable: may include myalgia, fatigue, anosmia/dysgeusia, shortness of breath |
| Cough | Common; can outlast the other symptoms by up to 3 weeks | Uncommon unless driven by postnasal drip | Common, often prominent | Common |
| Distinguishing clue | Gradual cluster of nasal/throat symptoms without a clear trigger | Clear seasonal or environmental trigger; personal or family history of atopy | Abrupt, severe systemic illness disproportionate to nasal symptoms | Exposure history; anosmia/dysgeusia; variable severity |
| Next step | Clinical diagnosis; no testing needed | Clinical diagnosis; allergy testing only if recurrent, severe, or the diagnosis is unclear | Clinical diagnosis; rapid antigen/PCR testing if antiviral therapy is being considered | PCR or rapid antigen testing per current local public health guidance |
History
- Symptom timeline and trajectory (gradual onset, peak day 2-4, expected improvement by day 7) — a course that does not fit this pattern should prompt reconsideration of the diagnosis.
- Associated symptoms: sore throat, cough, fever, ear pain, facial/sinus pain, wheeze.
- Screen specifically for the red flags above at every assessment.
- Vaccination status (influenza, pneumococcal, COVID-19), exposure history, and comorbidities that increase complication risk (asthma, COPD, immunocompromise, young infant age).
Examination
- Vital signs, including temperature — a genuinely high fever or tachypnea should prompt reconsideration of the diagnosis rather than reassurance.
- Ear exam in children, given the risk of otitis media as a complication.
- Oropharynx and neck exam if sore throat or lymphadenopathy is prominent, to screen for streptococcal pharyngitis or another cause.
- Chest auscultation if cough is prominent, to screen for wheeze or localized findings that would suggest a different diagnosis.
Investigations
- No laboratory or imaging investigation is needed for a straightforward, uncomplicated presentation — this is a clinical diagnosis.
- Consider influenza and/or COVID-19 testing per current local public health/testing guidance when the result would change management (e.g., antiviral candidacy in a high-risk patient) or is needed for public health purposes.
- Reserve chest x-ray, sinus imaging, or bloodwork for patients meeting red-flag criteria — these are not routine tests for viral rhinitis.
Treatment Targets
- Relieve nasal congestion and rhinorrhea.
- Reduce pain, headache, and fever.
- Reduce cough, particularly when it disrupts sleep.
- Minimize interference with work, school, and daily activities.
- Minimize the adverse effects of whatever therapy is chosen — match the specific agent to the specific bothersome symptom rather than defaulting to a multi-symptom combination product.
- Limit person-to-person transmission through hand and cough hygiene.
Choose Initial Treatment
Three symptom-targeted treatment tracks
Nasal (congestion, rhinorrhea, sneezing)
Topical or oral decongestants for congestion; intranasal ipratropium or a first-generation antihistamine for rhinorrhea and sneezing.
Cough
Honey is the best-supported option in eligible patients; antitussives and expectorants are not routinely recommended given insufficient evidence specific to the common cold.
Systemic (pain, headache, fever)
Acetaminophen or ibuprofen at standard age-appropriate doses; ASA is reserved for adults only given Reye syndrome risk in children and adolescents.
There is no cure and no disease-modifying therapy for viral rhinitis — every recommendation below is purely symptomatic. Match the specific agent to the specific symptom that is actually bothering the patient; do not default to a multi-symptom combination product when only one symptom needs treatment.
Nasal congestion, 1st line a topical intranasal decongestant (oxymetazoline or xylometazoline) for a maximum of 3-5 consecutive days.[2]
Nasal congestion, alternative oral pseudoephedrine, when a longer duration of action or a non-topical option is preferred, in a patient without a cardiovascular contraindication.
Rhinorrhea and sneezing intranasal ipratropium (does not treat congestion)[3] or a first-generation antihistamine such as diphenhydramine — the modest benefit here comes from the anticholinergic drying effect, not from blocking an allergic histamine response, since a cold is not an allergic process.[4]
Pain, headache, and fever acetaminophen or ibuprofen at standard age-appropriate doses; naproxen is a longer-acting alternative in adults and children over 12 years.
Cough honey (1 teaspoon at bedtime), in anyone 1 year of age or older — a genuinely evidence-supported option.[5]
Cough, not routinely recommended antitussives (dextromethorphan, codeine) and expectorants (guaifenesin) — evidence of benefit specific to the common cold is insufficient, on top of the pediatric restrictions below.
Pediatric age restriction — under 6 years: Health Canada states that non-prescription cough and cold medications (antihistamines, decongestants, antitussives, and expectorants) should not be used in children under 6 years of age, based on limited evidence of effectiveness in this age group together with reports of misuse, overdose, and rare serious adverse effects.[6]
Pediatric age restriction — under 18 years: Health Canada recommends that children and youth under 18 years of age not use cough and cold products that contain an opioid (e.g., codeine), regardless of the reason for the general product-category restriction above.[7]
Pediatric age restriction — under 1 year: avoid honey in infants under 12 months of age because of the risk of infant botulism.
Antibiotics are not indicated for uncomplicated viral rhinitis — this is a viral illness, and antibiotic use increases adverse effects without shortening the course.[8] See Common Errors to Avoid below; the Acute Bronchitis and Acute Rhinosinusitis chapters cover the fuller antibiotic-stewardship framing relevant to related upper respiratory presentations.
Non-Pharmacologic Treatment
- Maintain usual fluid intake to stay hydrated; there is no evidence that increasing fluid intake beyond normal improves recovery, but adequate hydration remains reasonable general advice.
- Rest as needed, though no studies specifically support this recommendation.
- Hand hygiene and cough/sneeze etiquette (into the elbow or a tissue that is then discarded) are the most effective measures to limit transmission to others.
- Avoid close contact with others while symptomatic, particularly during the first few days of illness.
- A mask or face covering in public settings may be reasonable to reduce transmission.
- Steam inhalation has insufficient evidence to recommend it and carries a real burn risk, particularly in children — advise caution if a patient chooses to try it, and ensure any vaporizer is cleaned regularly to prevent contamination.
Saline nasal irrigation
Saline nasal irrigation (0.9% NaCl) is a genuinely evidence-supported, low-risk, nonpharmacologic option — it may reduce nasal secretions and congestion and reduce the need for decongestants, in both children and adults.[9] Breast- or bottle-fed infants, who are obligate nose breathers, may particularly benefit from regular saline nasal drops to aid nasal clearance and improve mucociliary function.
Natural health products — an honest evidence review
Several natural health products are commonly asked about for cold treatment; the evidence for each is modest at best, and none should be presented to a patient as a reliably effective option.
- Zinc lozenges — a 2024 Cochrane review found that zinc supplementation may modestly shorten the duration of a cold, but the effect is inconsistent across studies and comes with an increased rate of adverse effects (chiefly unpleasant taste and nausea); dosing and duration have not been established with enough consistency to make a specific product recommendation.[10]
- Vitamin C — routine supplementation once a cold has started has not been shown to shorten its duration or reduce its severity in the general population; there is insufficient evidence to recommend it as a treatment.[11]
- Echinacea — evidence for both prevention and treatment is weak and inconsistent; not recommended.
- North American ginseng extract (e.g., Panax quinquefolius) — some evidence supports a modest reduction in the total time with upper respiratory symptoms when taken preventatively for several months before cold season, but there is insufficient evidence to recommend it once a cold has already started, and no safety data exist for children.
- Topical menthol/camphor preparations — not recommended in children under 2 years of age, and should never be applied directly under or in the nostrils at any age, given the risk of increased mucus production and reduced clearance leading to respiratory distress in children; camphor specifically carries a toxicity risk if ingested or misused.
- Probiotics — some evidence supports a modest reduction in upper respiratory infection frequency when taken for several months as a preventive measure, not as treatment once symptoms have started.
Special Populations
Pregnancy
Fever associated with a cold or influenza during pregnancy has been associated with an increased risk of certain birth defects, which is one reason to treat fever promptly in this population rather than letting it run its course.
First-generation antihistamines (brompheniramine, chlorpheniramine, diphenhydramine) are considered safe in pregnancy.
Oral decongestants (phenylephrine, pseudoephedrine) have conflicting reports of a possible small increase in specific malformations with first-trimester use — more evidence is needed before a clear recommendation can be made, so avoid routine first-trimester use and prefer a topical option if a decongestant is genuinely needed.
Topical decongestants (oxymetazoline, xylometazoline) are considered safe for short-term use (a maximum of 3-5 days) in pregnancy, although systemic absorption has not been fully characterized and some systemic effects (hypertension, respiratory depression, sedation) have been reported with xylometazoline specifically.
Acetaminophen is the preferred agent for fever, headache, and discomfort in pregnancy. Avoid NSAIDs in late pregnancy — risk of premature closure of the ductus arteriosus in the third trimester, and a potential reduction in amniotic fluid after 20 weeks' gestation.
High-dose vitamin C supplementation is not recommended in pregnancy for this self-limited condition — combined high-dose vitamin C and vitamin E supplementation has been associated with a higher incidence of intrauterine growth restriction in trial data evaluating pre-eclampsia prevention, which raises enough uncertainty that it should not be recommended for a self-limited illness like a cold. The safety of Echinacea in pregnancy has not been established, and ginseng's active component has shown teratogenic potential in animal studies — advise caution with both.
Breastfeeding
Intranasal saline and topical decongestants (oxymetazoline, xylometazoline) are preferred over oral decongestants during breastfeeding.
Honey is safe during breastfeeding — there is no risk of transferring botulism toxin to the breastfeeding infant through breast milk.
First-generation antihistamines and pseudoephedrine are generally considered safe during breastfeeding, but watch for infant drowsiness or irritability, and be aware that these agents — especially in combination — can reduce serum prolactin and milk supply; use the lowest effective dose and duration, and discontinue if a decrease in milk supply is observed.
Acetaminophen is the preferred agent for fever, headache, and discomfort during breastfeeding; NSAIDs are also considered safe.
Use Echinacea and ginseng with caution during breastfeeding given insufficient safety data.
Pediatrics
The pediatric age restrictions in Choose Initial Treatment above are the single most frequently tested pharmacist counselling point for this condition — non-prescription cough and cold products (antihistamines, decongestants, antitussives, expectorants) should not be used under 6 years of age, opioid-containing cough/cold products should not be used under 18 years of age, and honey should be avoided under 12 months of age because of infant botulism risk.[6]
ASA should never be used in a child or adolescent with a viral illness because of the risk of Reye syndrome — a rare but serious hepatic and neurologic illness strongly associated with aspirin use during a viral infection in this age group; acetaminophen or ibuprofen are the appropriate alternatives.[12]
In school-aged children (6 years and older), there have been few trials of antihistamine/decongestant use; weigh the risks of treatment carefully against the modest evidence of benefit before recommending routine use, even though these products are not restricted by age in this group the way they are under 6.
Older adults
Use decongestants (oral more than topical) with caution given a higher prevalence of hypertension, cardiovascular disease, diabetes, and benign prostatic hyperplasia in this population.
Avoid first-generation antihistamines (diphenhydramine, chlorpheniramine, brompheniramine) where possible — the Beers Criteria specifically recommend against this drug class in adults 65 years and older because of markedly increased confusion, delirium, and fall risk from the anticholinergic burden.
Monitoring & Follow-Up
Set expectations at the outset: symptoms typically peak by day 2-4 and improve by day 7, with the full course usually resolving within 10-14 days; cough specifically can persist up to 3 weeks in a substantial minority of patients even when everything else has resolved.
| What to monitor | How often | Endpoint of therapy | Action if not met |
|---|---|---|---|
| Cold symptoms (congestion, rhinorrhea, cough, sore throat) | Patient: daily. Pharmacist/prescriber: follow-up in 2-3 days if symptoms are not improving | Patient able to carry out daily activities and sleep adequately | Optimize nonpharmacologic measures; change or add a targeted therapy if the current approach is not effective |
| Drowsiness (adverse effect of a first-generation antihistamine) | Patient: daily, especially before driving or operating machinery | No significant drowsiness interfering with function | Move dosing to bedtime only, reduce the dose, or discontinue |
| Insomnia (adverse effect of an oral decongestant) | Patient: daily. Pharmacist/prescriber: check at 1 week if still in use | No insomnia | Move dosing to daytime only, or discontinue |
| Blood pressure (adverse effect of an oral decongestant, hypertensive patients only) | Check twice in the first week of use | No elevation above the patient's baseline | Stop the oral decongestant; trial a topical decongestant instead |
Common Errors to Avoid
- Recommending or prescribing an antibiotic for an uncomplicated cold — discoloured nasal discharge reflects the normal inflammatory course of a viral infection, not bacterial superinfection, and is not on its own an indication for antibiotics.[8]
- Letting a patient continue a topical intranasal decongestant beyond 3-5 days — the single most common preventable error in cold management, causing rebound congestion that is often worse than the original problem.[13]
- Recommending a combination cough/cold, antihistamine, or decongestant product for a child under 6 years of age.[6]
- Recommending or dispensing an opioid-containing cough/cold product (e.g., codeine) for anyone under 18 years of age.[7]
- Missing unintentional acetaminophen or NSAID double-dosing when a patient combines a multi-symptom combination product with a separate, single-ingredient analgesic — always ask what else the patient is already taking before recommending an additional product.
- Recommending ASA for fever or pain in a child or adolescent with a viral illness — Reye syndrome risk.[12]
- Framing a first-generation antihistamine's benefit for a cold as blocking an allergy — the mechanism here is anticholinergic drying, not antihistamine action against an allergic process, and the wrong expectation undermines informed consent about the sedation trade-off.
- Overlooking saline nasal irrigation as a genuinely evidence-supported, essentially risk-free option, in favour of reflexively recommending a decongestant.[9]
- Missing a secondary bacterial complication in a patient whose course is biphasic (initial improvement, then worsening) rather than simply prolonged — this pattern is a specific red flag, not just a cold taking longer than usual.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Analgesics and antipyretics
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Acetaminophen | Adults and children over 12 years: 325-650 mg PO every 4-6 hours PRN, maximum 4000 mg/day Children: 10-15 mg/kg PO every 4-6 hours PRN, maximum 5 doses/day or 75 mg/kg/day, whichever is less | Uncommon at recommended doses; hepatotoxicity with chronic overuse or overdose | Increased hepatotoxicity risk with chronic alcohol use. Many nonprescription combination products already contain acetaminophen -- check every product a patient is using to avoid inadvertent double-dosing. |
| Ibuprofen | Adults: 200-400 mg PO every 4-6 hours PRN, maximum 1200 mg/day for self-care Children over 6 months: 5-10 mg/kg PO every 6-8 hours PRN, maximum 40 mg/kg/day Children under 6 months: Not generally recommended | GI upset, rare GI bleeding; avoid with dehydration | Avoid combining with other NSAIDs or ASA. Ensure adequate fluid intake before use. |
| Naproxen (sodium) | Adults and children over 12 years: 220-550 mg PO every 8-12 hours PRN; maximum 1375 mg/day under supervision, 440 mg/day for self-care Children under 12 years: Not recommended | GI upset/bleeding, fluid retention | Same interaction profile as other NSAIDs -- increased bleeding risk with anticoagulants/SSRIs, reduced antihypertensive effect of ACE inhibitors/beta-blockers/diuretics. |
| Acetylsalicylic acid (ASA) | Adults only: 325-650 mg PO every 4-6 hours PRN, maximum 4000 mg/day Children and adolescents: Do not use -- Reye syndrome risk with a viral illness | GI upset, bleeding, tinnitus at high dose | Not recommended for routine cold symptom relief given safer alternatives are available; increased bleeding risk with anticoagulants. |
Anticholinergics, nasal
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Ipratropium (nasal spray) | Adults and children 5 years and older (0.06%): 2 sprays in each nostril 3-4 times daily PRN | Nosebleed, nasal dryness, dry mouth or throat | Effective for rhinorrhea and sneezing, but does not improve nasal congestion. Avoid accidental release into the eyes -- can cause pupil dilation, blurred vision, or precipitate acute angle-closure glaucoma. A separate, unrelated inhaled ipratropium product (Atrovent HFA) is a bronchodilator for asthma/COPD and must not be substituted for this nasal spray. |
Antihistamines, first-generation (oral)
Modest benefit at best, through an anticholinergic drying effect rather than blocking an allergic process -- sedation is a common trade-off.
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Diphenhydramine (oral) | Adults: 25-50 mg PO every 4-6 hours PRN, maximum 300 mg/day Children under 6 years: Not recommended | Sedation, dry mouth, urinary retention, next-day grogginess | Avoid in adults 65 years and older per the Beers Criteria given fall and delirium risk. Additive sedation with alcohol or other CNS depressants. |
Decongestants, nasal (topical)
Limit every agent in this class to a maximum of 3-5 consecutive days to avoid rebound congestion (rhinitis medicamentosa).
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Oxymetazoline | Adults and children 6 years and older (0.05%): 2-3 sprays or drops in each nostril every 12 hours PRN, maximum 2 doses/24 hours | Transient burning/stinging, nasal dryness; rebound congestion beyond 3-5 days | Preferred over an oral decongestant in pregnancy/breastfeeding when short-term use is genuinely needed. Contraindicated with a nonselective MAOI, or within 2 weeks of stopping one. |
| Xylometazoline | Adults and children 6 years and older (0.05% or 0.1%): 1-2 sprays, or 2-3 drops, in each nostril every 8-10 hours PRN, maximum 3 doses/24 hours | Transient burning/stinging, nasal dryness; rebound congestion beyond 3-5 days | Same MAOI contraindication and rebound-congestion ceiling as oxymetazoline. |
| Phenylephrine (nasal) | Adults and children 12 years and older (0.25% or 0.5%): 2-3 sprays in each nostril no more than every 4 hours, maximum 6 doses/24 hours | Transient burning/stinging, nasal dryness; rebound congestion beyond 3-5 days | Shorter duration of action requires more frequent dosing than oxymetazoline/xylometazoline. Same MAOI contraindication. A separate, unrelated injectable phenylephrine product is a vasopressor used in anesthesia and shock -- do not confuse the two. |
Decongestants, oral
There is no published evidence supporting oral decongestant, antihistamine, or antihistamine/decongestant combination use in children under 6 years of age.
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Pseudoephedrine | Adults and children 12 years and older: 60 mg PO every 4-6 hours PRN, or 120 mg extended-release PO every 12 hours; maximum 240 mg/24 hours Children 6-11 years: 30 mg PO every 4-6 hours PRN; maximum 120 mg/24 hours Children under 6 years: Not recommended | Insomnia, tremor, irritability, headache, palpitations, tachycardia, hypertension | Contraindicated with severe hypertension, coronary artery disease, or concurrent/recent (14-day) MAOI use. Use with caution in cardiovascular disease, diabetes, hyperthyroidism, prostatic hyperplasia, and angle-closure glaucoma. Sold behind the pharmacy counter in Canada given its use as a methamphetamine precursor. |
Decongestant/antihistamine combination products
Combination antihistamine-decongestant-analgesic products show, at best, a modest overall improvement in feeling unwell compared with placebo, without clear evidence of benefit for individual symptoms, and an increased rate of adverse effects -- favour single-ingredient, symptom-targeted therapy over these products whenever practical.<cite data-reference-id="a9581179-aa08-41ea-8e9c-f68d5658410a"></cite> For any combination product, dose according to the specific active-ingredient content stated on that product's label rather than assuming a standard dose -- strengths vary widely between brands. The core counselling risk with this whole category is unintentional double-dosing: many of these products already contain acetaminophen or ibuprofen, so confirm a patient is not adding a separate analgesic on top.
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Chlorpheniramine / ibuprofen / pseudoephedrine | Dosing: Per the specific product label -- consult the package insert for the exact strength being dispensed | Combines the adverse effect profile of each component -- sedation, GI upset, insomnia, tremor, hypertension | Evidence for antihistamine/decongestant combinations in children under 6 years of age is lacking; not recommended in that age group. |
| Acetaminophen / diphenhydramine | Dosing: Per the specific product label -- consult the package insert for the exact strength being dispensed | Combines acetaminophen's overdose-related hepatotoxicity risk with diphenhydramine's sedation/anticholinergic effects | A common source of unintentional acetaminophen double-dosing when combined with a separate cold or pain product -- always ask what else the patient is taking. |
Antitussives and expectorants -- insufficient evidence for the common cold
Dextromethorphan, codeine, and guaifenesin are not routinely recommended for cold-associated cough given insufficient evidence of benefit specific to this condition; if a cough suppressant is genuinely wanted despite this, the pediatric restrictions above still apply in full.
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Dextromethorphan | Adults and children over 12 years: 30 mg PO every 6-8 hours PRN, maximum 120 mg/day | Rare nausea, drowsiness, dizziness | Not recommended in children under 6 years of age. Avoid with, or within 2 weeks of, an MAOI. |
| Codeine | Adults: 10-20 mg PO every 4-6 hours PRN, maximum 120 mg/day | Sedation, nausea/vomiting, constipation | Not for use under 18 years of age per Health Canada. Weak evidence for benefit specifically in the common cold. |
Honey
The single best-supported option for bothersome cough in an eligible patient.
| Drug | Dosage | Adverse effects | Comments |
|---|---|---|---|
| Honey | Adults and children over 1 year: 1 teaspoon (5 mL) at bedtime | None known when pasteurized | Use pasteurized honey only. Avoid honey made from Rhododendron species due to grayanotoxin risk. Avoid entirely in infants under 12 months of age given the risk of infant botulism. |
References
- Treatment of the Common Cold — American Family Physician (DeGeorge KC, Ring DJ, Dalrymple SN). Am Fam Physician 2019;100(5):281-289
- Nasal decongestants in monotherapy for the common cold — Cochrane Database of Systematic Reviews (Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML). Cochrane Database Syst Rev 2016;10:CD009612
- Intranasal ipratropium bromide for the common cold — Cochrane Database of Systematic Reviews (AlBalawi ZH, Othman SS, Alfaleh K). Cochrane Database Syst Rev 2013;(6):CD008231
- Antihistamines for the common cold — Cochrane Database of Systematic Reviews (De Sutter AI, Saraswat A, van Driel ML). Cochrane Database Syst Rev 2015;(11):CD009345
- Honey for acute cough in children — Cochrane Database of Systematic Reviews (Oduwole O, Udoh EE, Oyo-Ita A, Meremikwu MM). Cochrane Database Syst Rev 2018;(4):CD007094
- Concerns about children's medication: avoiding cough and cold medications — Health Canada. Health Canada consumer safety information, updated
- Health Canada recommends that children and youth not use cough and cold products that contain opioids — Health Canada. Recall/alert, February 18, 2019
- Antibiotics for the common cold and acute purulent rhinitis — Cochrane Database of Systematic Reviews (Kenealy T, Arroll B). Cochrane Database Syst Rev 2025;(11):CD000247
- Saline nasal irrigation for acute upper respiratory tract infections — Cochrane Database of Systematic Reviews (King D, Mitchell B, Williams CP, Spurling GK). Cochrane Database Syst Rev 2015;(4):CD006821
- Zinc for prevention and treatment of the common cold — Cochrane Database of Systematic Reviews (Nault D, Machingo TA, Shipper AG, et al.). Cochrane Database Syst Rev 2024;(5):CD014914
- Vitamin C for preventing and treating the common cold — Cochrane Database of Systematic Reviews (Hemila H, Chalker E). Cochrane Database Syst Rev 2013;(1):CD000980
- Reye's syndrome in the United States from 1981 through 1997 — New England Journal of Medicine (Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB). N Engl J Med 1999;340(18):1377-1382
- Rhinitis medicamentosa: aspects of pathophysiology and treatment — Allergy (Graf P). Allergy 1997;52(40 Suppl):28-34
- Oral antihistamine-decongestant-analgesic combinations for the common cold — Cochrane Database of Systematic Reviews (De Sutter AIM, Eriksson L, van Driel ML). Cochrane Database Syst Rev 2022;(1):CD004976
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.